Derazantinib hydrochloride is under clinical development by Basilea Pharmaceutica and currently in Phase III for Hepatocellular Carcinoma. According to GlobalData, Phase III drugs for Hepatocellular Carcinoma have a 45% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Derazantinib hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Derazantinib hydrochloride overview

Deranzantinib hydrchloride (ARQ-087) is under development for the treatment of intrahepatic cholangiocarcinoma (iCCA), adenocarcinoma of the gastroesophageal junction, adrenocortical tumors, advanced solid tumors and urothelial cell carcinoma. The drug candidate is administered orally. ARQ-087 is an inhibitor of pan-fibroblast growth factor receptor (FGFR) and CSF1R. The drug candidate is based on proprietary structure-based drug design technology known as the ArQule Kinase Inhibitor Platform (AKIP).

Basilea Pharmaceutica overview

Basilea Pharmaceutica (Basilea) is a biopharmaceutical company that develops and markets antibiotics, antifungals and oncology drugs. The company products are for increasing resistance and non-response to present treatment options for various therapeutic areas such as cancer, bacterial infections, and fungal infections. Basilea also conducts research in the areas of anti-infectives, cancer, and bacterial or fungal strains. It discovers drugs with the help of various technologies such as genomics, assay development, cell biology and others. The company also operates in France, the UK, China, Germany, Spain, Switzerland, Italy, and Denmark. Basilea is headquartered in Basel, Switzerland.

For a complete picture of Derazantinib hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.